IHH HEALTHCARE |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.27 MYR | +0.32% |
|
+2.96% | +3.98% |
| Apr. 05 | IHH Healthcare Names CFO | MT |
| Apr. 05 | IHH Healthcare Berhad Appoints Dilip Kadambi as Group Chief Financial Officer | CI |
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.42 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +3.65% | 11.52B | B+ | ||
| -22.63% | 15.76B | B+ | ||
| +3.60% | 12.34B | B | ||
| +10.01% | 11.02B | B+ | ||
| +24.00% | 8.28B | B | ||
| -2.19% | 7.8B | A- | ||
| +20.75% | 7.2B | D | ||
| +4.53% | 6.67B | B- | ||
| +49.97% | 4.64B | - | ||
| -5.01% | 4.25B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- IHH Stock
- Ratings IHH Healthcare
